4,623 Shares in Exact Sciences Co. (NASDAQ:EXAS) Purchased by SageView Advisory Group LLC

SageView Advisory Group LLC purchased a new stake in Exact Sciences Co. (NASDAQ:EXAS) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 4,623 shares of the medical research company’s stock, valued at approximately $342,000.

Other large investors have also recently modified their holdings of the company. Capital World Investors raised its stake in Exact Sciences by 7.8% in the fourth quarter. Capital World Investors now owns 7,468,145 shares of the medical research company’s stock valued at $552,493,000 after purchasing an additional 539,498 shares in the last quarter. Artisan Partners Limited Partnership grew its position in Exact Sciences by 12.8% in the fourth quarter. Artisan Partners Limited Partnership now owns 4,470,278 shares of the medical research company’s stock worth $330,711,000 after acquiring an additional 508,764 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in Exact Sciences by 11.5% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,858,380 shares of the medical research company’s stock valued at $137,483,000 after acquiring an additional 192,372 shares during the last quarter. Norges Bank purchased a new stake in Exact Sciences during the fourth quarter valued at about $120,308,000. Finally, Jennison Associates LLC lifted its stake in Exact Sciences by 94.0% during the fourth quarter. Jennison Associates LLC now owns 1,360,917 shares of the medical research company’s stock worth $100,681,000 after purchasing an additional 659,235 shares during the last quarter. Institutional investors own 88.82% of the company’s stock.

Analysts Set New Price Targets

EXAS has been the topic of several recent research reports. BTIG Research reduced their price objective on Exact Sciences from $85.00 to $80.00 and set a “buy” rating on the stock in a research report on Thursday, May 9th. Canaccord Genuity Group decreased their price target on shares of Exact Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, May 9th. Citigroup cut their price objective on shares of Exact Sciences from $100.00 to $80.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. Jefferies Financial Group began coverage on shares of Exact Sciences in a research report on Monday, June 3rd. They issued a “buy” rating and a $75.00 target price on the stock. Finally, TheStreet lowered shares of Exact Sciences from a “c-” rating to a “d+” rating in a research report on Monday, February 26th. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $93.07.

Exact Sciences Price Performance

EXAS opened at $41.92 on Thursday. The stock’s 50 day moving average price is $53.57 and its 200-day moving average price is $61.28. Exact Sciences Co. has a 52-week low of $41.08 and a 52-week high of $100.77. The stock has a market capitalization of $7.74 billion, a PE ratio of -31.76 and a beta of 1.26. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.45 and a current ratio of 1.64.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Wednesday, May 8th. The medical research company reported ($0.50) EPS for the quarter, hitting the consensus estimate of ($0.50). The business had revenue of $637.52 million during the quarter, compared to analyst estimates of $624.95 million. Exact Sciences had a negative net margin of 9.48% and a negative return on equity of 7.12%. On average, equities research analysts predict that Exact Sciences Co. will post -1.15 EPS for the current year.

Insiders Place Their Bets

In other Exact Sciences news, CEO Kevin T. Conroy sold 1,155 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $60.15, for a total transaction of $69,473.25. Following the transaction, the chief executive officer now owns 1,156,191 shares in the company, valued at approximately $69,544,888.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Sarah Condella sold 2,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $70.00, for a total transaction of $140,000.00. Following the sale, the executive vice president now owns 71,787 shares in the company, valued at approximately $5,025,090. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Kevin T. Conroy sold 1,155 shares of the stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $60.15, for a total transaction of $69,473.25. Following the completion of the transaction, the chief executive officer now owns 1,156,191 shares of the company’s stock, valued at $69,544,888.65. The disclosure for this sale can be found here. Insiders sold 5,498 shares of company stock worth $370,105 over the last three months. Company insiders own 1.36% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.